MindRank Pharma and Henlius Announce Strategic Collaboration to Co-Develop AI-Powered Platforms for Next-Generation ADCs and Anti-Aging Therapies

Shanghai Henlius Biotech, Inc. (2696.HK) is an international innovative biopharmaceutical company dedicated to providing affordable high-quality biologics to patients worldwide. Its products cover areas such as oncology, autoimmune diseases, and ophthalmic diseases. The company has launched five products in China, two internationally, with 19 indications approved. Three marketing applications have been accepted by the Chinese NMPA, the U.S. FDA, and the European EMA, respectively. Since its establishment in 2010, Henlius has built an integrated biopharmaceutical platform with efficient and innovative core competencies spanning the entire industry chain of R&D, manufacturing, and commercial operations. The company has established a comprehensive and efficient global innovation hub, adhering to international Good Manufacturing Practice (GMP) standards for production and quality control, continuously strengthening its integrated manufacturing platform. Notably, both the Xuhui Shanghai facility and Songjiang Base (I) have received GMP certifications from China and the EU.

Shanghai Henlius Biotech, Inc. has proactively laid out a diversified and high-quality product pipeline, covering more than 20 innovative monoclonal antibodies, and comprehensively advanced tumor immunotherapy combination therapies based on its proprietary anti-PD-1 monoclonal antibody HANSIZHUANG (serplulimab). Following the successive approvals of China’s first biosimilar HLX01 (rituximab), China’s first self-developed monoclonal antibody drug approved in both China and Europe, HLX02 (trastuzumab, European trade name: Zercepac®, Australian trade names: Tuzucip® and Trastucip®), HDAYFAR (adalimumab), and HANBEITAI (bevacizumab), the innovative product HANSIZHUANG (serplulimab) has been approved for treating microsatellite instability-high (MSI-H) solid tumors, squamous non-small cell lung cancer, extensive-stage small cell lung cancer, and esophageal squamous cell carcinoma. It has also become the world’s first approved anti-PD-1 monoclonal antibody for first-line treatment of small cell lung cancer. The company is also conducting over 30 clinical trials across 16 products globally, with out-licensing fully covering mainstream biopharmaceutical markets in Europe and America as well as numerous emerging markets.

MindRank is a clinical-stage AI-driven innovative drug discovery company. The company’s vision is to continuously deliver differentiated and high-clinical-value drug candidates by promoting the integration of various cutting-edge technologies in artificial intelligence and new drug development, thereby helping more lives regain health.

The AI pharmaceutical solution of the company was once rated as one of the "11 most important AI drug R&D breakthrough achievements globally from 2018 to 2020" by the authoritative European and American institution Deep Pharma Intelligence. In 2023, it was selected for Forbes' "Forbes Asia 100 to Watch" list, with only 11 start-up companies from mainland China making the list.

For more information, please visit the website: www.mindrank.ai

Cooperation: bd@mindrank.ai

Other: info@mindrank.ai